À§¸¶ºñ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Áúȯ ÀûÀÀÁõº°, À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Gastroparesis Treatment Market, By Drug Class, By Disease Indication, By Type, By Route of Administration, By Distribution Channel, By Geography
»óǰÄÚµå : 1672703
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,256,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,732,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,903,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀåÀº 2025³â¿¡´Â 83¾ï 3,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 115¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 83¾ï 3,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 4.80% 2032³â °¡Ä¡ ¿¹Ãø 115¾ï 8,000¸¸ ´Þ·¯
µµÇ¥. À§¸¶ºñ Ä¡·á ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
Gastroparesis Treatment Market-IMG1

¼¼°è À§ºÎÀü¸¶ºñ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´°ú Ư¹ß¼º À§ºÎÀü¸¶ºñ À¯º´·ü Áõ°¡°¡ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À§ºÎÀü ¸¶ºñ(À§ ¹èÃâ Áö¿¬)´Â À§°¡ ³»¿ë¹°À» ºñ¿ì´Â µ¥ ½Ã°£ÀÌ ³Ê¹« ¿À·¡ °É¸®´Â ¸¸¼ºÁúȯÀÔ´Ï´Ù. À§¸¶ºñ ȯÀÚ´Â ½Ä»ç ÈÄ ¸Þ½º²¨¿ò, ±¸Åä, º¹ºÎ ÆØ¸¸°¨, Æ÷¸¸°¨À» °æÇèÇÕ´Ï´Ù. ÇöÀç À§ºÎÀü¸¶ºñ¸¦ ¿ÏÄ¡ÇÒ ¼ö ÀÖ´Â Ä¡·á¹ýÀº ¾øÀ¸¸ç, ÇöÀç »ç¿ë °¡´ÉÇÑ Ä¡·á¹ýÀº Áõ»ó Á¶Àý¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ½Å¾à °³¹ß°ú °ü·ÃµÈ ¿¬±¸°³¹ß Ȱµ¿ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è À§ºÎÀü¸¶ºñ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´ Àα¸ Áõ°¡, Ư¹ß¼º À§ºÎÀü¸¶ºñ À¯º´·ü Áõ°¡, À§ºÎÀü¸¶ºñ¿¡ ´ëÇÑ ±¹¹Î°ú ÀÇ»çÀÇ ÀÎ½Ä Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª °æ±¸¿ë ¾à¹°¿¡ µû¸¥ ȯÀÚ ¼øÀÀµµ ÀúÇÏ, È¿°úÀûÀÎ Ä¡·á¹ýÀÇ ºÎÀç, ¾à¼öó¸®ÀÇ ºÎÀÛ¿ë µîÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ´õ ³ªÀº È¿´É°ú ºÎÀÛ¿ëÀÌ ÀûÀº ½Å¾àÀÇ °³¹ßÀº ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ À§ºÎÀü¸¶ºñ Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è À§ºÎÀü ¸¶ºñ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ °³¿äÀ» Á¦°øÇÕ´Ï´Ù.

º» Á¶»çÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷¿¡´Â Abbott Laboratories, Medtronic, Mylan, Pfizer, Johnson &Johnson Services, Bausch Health, Antrotrans, Alembic Pharmaceuticals µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è À§¸¶ºñ Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è À§¸¶ºñ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦5Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, Áúȯ ÀûÀÀÁõº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦9Àå ¼¼°èÀÇ À§¸¶ºñ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gastroparesis Treatment Market is estimated to be valued at USD 8.33 Bn in 2025 and is expected to reach USD 11.58 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.8% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 8.33 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 4.80% 2032 Value Projection: USD 11.58 Bn
Figure. Gastroparesis Treatment Market Share (%), By Region 2025
Gastroparesis Treatment Market - IMG1

Global gastroparesis treatment market growth is driven by rising prevalence of diabetes and idiopathic gastroparesis. Gastroparesis, or delayed stomach emptying, is a chronic disorder, in which the stomach takes too long to empty its contents. Patients suffering from gastroparesis experience nausea, vomiting, bloating and fullness after eating. Currently, there is no cure for gastroparesis and the available treatment options focus on managing the symptoms. Rising research and development activities related to new drug development can drive the market growth.

Market Dynamics:

Global gastroparesis treatment market growth is driven by factors such as increasing diabetic population, rising prevalence of idiopathic gastroparesis, growing awareness about gastroparesis among people and physicians. However, poor patient compliance associated with oral medication, non-availability of effective treatment and side effects of drug therapies can hamper the market growth. Development of novel drugs with better efficacy and less side effects can offer lucrative growth opportunities in the market.

Key features of the study:

This report provides in-depth analysis of the global gastroparesis treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global gastroparesis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Abbott Laboratories, Medtronic, Mylan, Pfizer, Johnson & Johnson Services, Bausch Health, Antrotrans, Alembic Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastroparesis treatment market

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Gastroparesis Treatment Market, By Drug Class, 2020-2032, (USD Bn)

5. Global Gastroparesis Treatment Market, By Disease Indication, 2020-2032, (USD Bn)

6. Global Gastroparesis Treatment Market, By Type, 2020-2032, (USD Bn)

7. Global Gastroparesis Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

8. Global Gastroparesis Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

9. Global Gastroparesis Treatment Market, By Region, 2020 - 2032, (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â